title: HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tsutsumi
authors.forename: Reiki
authors.initials: R
authors.lastname: Ogasawara
authors.forename: Naohiro
authors.initials: N
authors.lastname: Miyashita
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis*; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000821:virology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride